Get the Stockscreener App
5.25
3.55%
0.18
After Hours:
5.25
Valneva Se Adr stock is traded at $5.25, with a volume of 240.53K.
It is up +3.55% in the last 24 hours and up +21.53% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
See More
Previous Close:
$5.07
Open:
$5.07
24h Volume:
240.53K
Relative Volume:
5.38
Market Cap:
$426.29M
Revenue:
$163.13M
Net Income/Loss:
$-34.75M
P/E Ratio:
-10.19
EPS:
-0.5152
Net Cash Flow:
$-231.66M
1W Performance:
+10.76%
1M Performance:
+21.53%
6M Performance:
-27.08%
1Y Performance:
-35.58%
1-Day Range:
$4.96
$5.3397
1-Week Range:
$4.71
$5.3397
52-Week Range:
$3.62
$9.50
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
5.25 | 426.29M | 163.13M | -34.75M | -231.66M | -0.5152 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock - Yahoo Finance
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine - GlobeNewswire Inc.
VALNEVA - GlobeNewswire Inc.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock - Yahoo Finance
Valneva SE earnings missed by $0.02, revenue fell short of estimates - Investing.com
Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target - Investing.com
Valneva SE Declaration of shares and voting rights - GlobeNewswire Inc.
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy - Investing.com
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy By Investing.com - Investing.com South Africa
In-Depth Examination Of 6 Analyst Recommendations For Valneva - Benzinga
Valneva shares hold strong with buy rating on Lyme vaccine data - Investing.com
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know - MSN
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock - Zacks Investment Research
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3% - Yahoo Finance
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine - Zacks Investment Research
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval - Yahoo Finance
Earnings call: Valneva reports robust growth and strategic R&D focus By Investing.com - Investing.com South Africa
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why - Nasdaq
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why - Yahoo Finance
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe - Zacks Investment Research
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal - Yahoo Finance
5 Top Health Care Stocks To Watch In The Stock Market Today - Stock Market
Valneva Stock Is Jumping on European Vaccine Supply Deal - Barron's
Valneva Stock Surges After EU Vaccine Deal - Investing.com
Valneva Shares Off 12% On Share Offering News By Investing.com - Investing.com UK
Valneva (VALN) Reports Positive Data From COVID Vaccine Study - Nasdaq
Valneva Stock Plunges as U.K. Drops Covid-19 Vaccine Deal - Barron's
EU set to sign off new Pfizer vaccine contract as soon as Friday - Luxembourg Times
Shareholder Structure - Valneva
Stock Price - Valneva
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):